This article was originally published in The Gray Sheet
Harvard cardiologist and device safety expert William Maisel sees a parallel "loophole" in FDA's model for assessing modifications to existing PMA products, which he says allows too many products on the market by means of a PMA supplement, which is less rigorous than a full PMA application.
You may also be interested in...
FDA finalized guidelines Dec. 11 explaining what PMA supplement submissions are required for certain product modifications, largely mirroring 2007 draft guidance that device makers considered "incomplete.
P&G’s oral care business drove 35% of total category market growth in the firm’s fiscal 2020 and exemplifies its growth strategy for all segments – grow entire categories rather than take competitors’ market share, says CFO Jon Moeller.
The Pink Sheet explains the procedures underpinning the UK’s emergency use authorization of the Pfizer/BioNTech COVID-19 vaccine.